JP2019526542A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019526542A5 JP2019526542A5 JP2019505245A JP2019505245A JP2019526542A5 JP 2019526542 A5 JP2019526542 A5 JP 2019526542A5 JP 2019505245 A JP2019505245 A JP 2019505245A JP 2019505245 A JP2019505245 A JP 2019505245A JP 2019526542 A5 JP2019526542 A5 JP 2019526542A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- composition according
- glyceride
- weight
- amount ranging
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims description 76
- 125000005456 glyceride group Chemical group 0.000 claims description 23
- 229920002675 Polyoxyl Polymers 0.000 claims description 15
- -1 cholesterol sulfates Chemical class 0.000 claims description 13
- 208000032928 Dyslipidaemia Diseases 0.000 claims description 10
- 208000017170 Lipid metabolism disease Diseases 0.000 claims description 10
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims description 10
- 239000004094 surface-active agent Substances 0.000 claims description 9
- 208000031226 Hyperlipidaemia Diseases 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- 230000004064 dysfunction Effects 0.000 claims description 8
- 229920006395 saturated elastomer Polymers 0.000 claims description 8
- 235000012000 cholesterol Nutrition 0.000 claims description 7
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Natural products C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 7
- 201000010099 disease Diseases 0.000 claims description 7
- 208000028867 ischemia Diseases 0.000 claims description 7
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 7
- 239000002245 particle Substances 0.000 claims description 7
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 claims description 6
- 229960002446 octanoic acid Drugs 0.000 claims description 6
- 229940049964 oleate Drugs 0.000 claims description 6
- 208000024891 symptom Diseases 0.000 claims description 6
- 125000000400 lauroyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 5
- 125000003696 stearoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 5
- 208000001395 Acute radiation syndrome Diseases 0.000 claims description 4
- 201000001320 Atherosclerosis Diseases 0.000 claims description 4
- 206010068142 Radiation sickness syndrome Diseases 0.000 claims description 4
- 208000027418 Wounds and injury Diseases 0.000 claims description 4
- 230000030833 cell death Effects 0.000 claims description 4
- 230000006378 damage Effects 0.000 claims description 4
- 208000014674 injury Diseases 0.000 claims description 4
- 210000000056 organ Anatomy 0.000 claims description 4
- 206010040882 skin lesion Diseases 0.000 claims description 4
- 231100000444 skin lesion Toxicity 0.000 claims description 4
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 claims description 3
- GHVNFZFCNZKVNT-UHFFFAOYSA-N Decanoic acid Natural products CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 3
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 3
- 229930195729 fatty acid Natural products 0.000 claims description 3
- 239000000194 fatty acid Substances 0.000 claims description 3
- 208000019423 liver disease Diseases 0.000 claims description 3
- INBGSXNNRGWLJU-ZHHJOTBYSA-N 25-hydroxycholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@@H](CCCC(C)(C)O)C)[C@@]1(C)CC2 INBGSXNNRGWLJU-ZHHJOTBYSA-N 0.000 claims description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 2
- PIUZYOCNZPYXOA-ZHHJOTBYSA-N [(3s,8s,9s,10r,13r,14s,17r)-17-[(2r)-6-hydroxy-6-methylheptan-2-yl]-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl] hydrogen sulfate Chemical compound C1C=C2C[C@@H](OS(O)(=O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@@H](CCCC(C)(C)O)C)[C@@]1(C)CC2 PIUZYOCNZPYXOA-ZHHJOTBYSA-N 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- BHYOQNUELFTYRT-UHFFFAOYSA-N Cholesterol sulfate Natural products C1C=C2CC(OS(O)(=O)=O)CCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 BHYOQNUELFTYRT-UHFFFAOYSA-N 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- BHYOQNUELFTYRT-DPAQBDIFSA-N cholesterol sulfate Chemical compound C1C=C2C[C@@H](OS(O)(=O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 BHYOQNUELFTYRT-DPAQBDIFSA-N 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 230000013190 lipid storage Effects 0.000 claims 1
- 208000017520 skin disease Diseases 0.000 claims 1
- 239000004359 castor oil Substances 0.000 description 4
- 235000019438 castor oil Nutrition 0.000 description 4
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 4
- 201000004624 Dermatitis Diseases 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- WECGLUPZRHILCT-GSNKCQISSA-N 1-linoleoyl-sn-glycerol Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(=O)OC[C@@H](O)CO WECGLUPZRHILCT-GSNKCQISSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- AOBORMOPSGHCAX-UHFFFAOYSA-N Tocophersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 229940113116 polyethylene glycol 1000 Drugs 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022047697A JP2022084831A (ja) | 2016-08-02 | 2022-03-24 | 酸素化コレステロールサルフェート、並びにポリアルキレングリコール、カルボキシメチルセルロース、及びポリオキシルグリセリドのうち少なくとも１種を含む組成物 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662370200P | 2016-08-02 | 2016-08-02 | |
| US62/370,200 | 2016-08-02 | ||
| US201762470834P | 2017-03-13 | 2017-03-13 | |
| US62/470,834 | 2017-03-13 | ||
| PCT/US2017/044934 WO2018026837A1 (en) | 2016-08-02 | 2017-08-01 | Compositions comprising oxygenated cholesterol sulfate and at least one of polyalkylene glycol, carboxymethyl cellulose and polyoxylglyceride |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022047697A Division JP2022084831A (ja) | 2016-08-02 | 2022-03-24 | 酸素化コレステロールサルフェート、並びにポリアルキレングリコール、カルボキシメチルセルロース、及びポリオキシルグリセリドのうち少なくとも１種を含む組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019526542A JP2019526542A (ja) | 2019-09-19 |
| JP2019526542A5 true JP2019526542A5 (enExample) | 2020-09-03 |
| JP7048576B2 JP7048576B2 (ja) | 2022-04-05 |
Family
ID=61074228
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019505245A Active JP7048576B2 (ja) | 2016-08-02 | 2017-08-01 | 酸素化コレステロールサルフェート、並びにポリアルキレングリコール、カルボキシメチルセルロース、及びポリオキシルグリセリドのうち少なくとも１種を含む組成物 |
| JP2022047697A Ceased JP2022084831A (ja) | 2016-08-02 | 2022-03-24 | 酸素化コレステロールサルフェート、並びにポリアルキレングリコール、カルボキシメチルセルロース、及びポリオキシルグリセリドのうち少なくとも１種を含む組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022047697A Ceased JP2022084831A (ja) | 2016-08-02 | 2022-03-24 | 酸素化コレステロールサルフェート、並びにポリアルキレングリコール、カルボキシメチルセルロース、及びポリオキシルグリセリドのうち少なくとも１種を含む組成物 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20200222430A1 (enExample) |
| EP (1) | EP3493810A4 (enExample) |
| JP (2) | JP7048576B2 (enExample) |
| KR (1) | KR102462275B1 (enExample) |
| CN (1) | CN109922811B (enExample) |
| AU (1) | AU2017305305A1 (enExample) |
| BR (1) | BR112019001225A2 (enExample) |
| CA (1) | CA3031215A1 (enExample) |
| IL (1) | IL264391A (enExample) |
| MX (1) | MX391441B (enExample) |
| TW (1) | TW201818946A (enExample) |
| WO (1) | WO2018026837A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006047022A1 (en) | 2004-10-25 | 2006-05-04 | Virginia Commonwealth University | Nuclear sulfated oxysterol, potent regulator of cholesterol homeostasis, for therapy of hypercholesterolemia, hyperlipidemia, and atherosclerosis |
| EA201990684A1 (ru) | 2013-12-24 | 2020-12-30 | Вирджиния Коммонвелт Юниверсити | Способы применения оксигенированных холестеролсульфатов (ocs) |
| IL298681A (en) | 2016-08-02 | 2023-01-01 | Univ Virginia Commonwealth | Preparations |
| WO2021005399A1 (en) * | 2019-07-08 | 2021-01-14 | The University Of Hong Kong | Compositions and methods for clearing tissue |
| JP7830313B2 (ja) * | 2019-09-30 | 2026-03-16 | デュレクト コーポレーション | アルコール性肝炎の処置 |
| CN115103591B (zh) * | 2019-12-27 | 2026-06-19 | 度勒科特公司 | 结晶性和液体结晶性25-羟基-胆甾-5-烯-3-硫酸钠及其制备方法 |
| CA3170320A1 (en) * | 2020-02-11 | 2021-08-19 | Durect Corporation | Treatment of infectious diseases |
| ES3004508T3 (en) * | 2020-04-15 | 2025-03-12 | Gruenenthal Gmbh | Resiniferatoxin compositions |
| CN115803061A (zh) * | 2020-05-22 | 2023-03-14 | 度勒科特公司 | 非酒精性脂肪性肝炎(nash)的治疗 |
| JP2023527153A (ja) * | 2020-05-22 | 2023-06-27 | デュレクト コーポレーション | 非アルコール性脂肪性肝炎（ｎａｓｈ）の処置 |
| CA3187310A1 (en) | 2020-06-26 | 2021-12-30 | Durect Corporation | Use of oxygenated cholesterol sulfates for treating autoimmune conditions |
| US20240425545A1 (en) * | 2021-06-25 | 2024-12-26 | Durect Corporation | 25-Hydroxy-Cholest-5-En-3-Sulfate Choline and Methods for Preparing, and Uses of, Same |
| CN114306350B (zh) * | 2022-01-13 | 2023-01-24 | 四川大学华西医院 | 胆固醇硫酸盐在制备预防脓毒症的药物中的用途 |
| CN114646702B (zh) * | 2022-03-03 | 2023-01-06 | 四川大学华西医院 | 胆固醇硫酸酯检测试剂在制备脓毒症辅助诊断、治疗效果监测和预后评估试剂盒中的用途 |
| WO2024136884A1 (en) * | 2022-12-23 | 2024-06-27 | Durect Corporation | Salts including crystalline salts of 25-hydroxy-cholest-5-en-3-sulfate and methods for preparing same |
| CN121695995A (zh) * | 2024-09-18 | 2026-03-20 | 深圳翰宇药业股份有限公司 | 一种多肽药物的粉碎方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6248363B1 (en) * | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| IS6633A (is) * | 2002-11-22 | 2004-05-23 | Omega Farma Ehf. | Samsetningar af fínasteríð töflum |
| US8399441B2 (en) * | 2004-10-25 | 2013-03-19 | Virginia Commonwealth University | Nuclear sulfated oxysterol, potent regulator of lipid homeostasis, for therapy of hypercholesterolemia, hypertriglycerides, fatty liver diseases, and atherosclerosis |
| WO2006047022A1 (en) | 2004-10-25 | 2006-05-04 | Virginia Commonwealth University | Nuclear sulfated oxysterol, potent regulator of cholesterol homeostasis, for therapy of hypercholesterolemia, hyperlipidemia, and atherosclerosis |
| US20090149434A1 (en) * | 2005-09-29 | 2009-06-11 | Joseph Podolski | Formulations with improved bioavailability, comprising a steroid derivative and a polyglycolysed glyceride |
| EP1983972A4 (en) | 2006-02-13 | 2012-01-25 | Wellstat Therapeutics Corp | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS |
| US8003795B2 (en) | 2007-06-22 | 2011-08-23 | Cvi Pharmaceuticals Limited | Compounds and compositions for reducing lipid levels |
| US9034859B2 (en) * | 2011-04-06 | 2015-05-19 | Virginia Commonwealth University | Sulfated oxysterol and oxysterol sulfation by hydroxysterol sulfotransferase promote lipid homeostasis and liver proliferation |
| CN104220450B (zh) * | 2012-04-12 | 2016-07-06 | 弗吉尼亚联邦大学 | 用于治疗代谢障碍、高脂血症、糖尿病、脂肪肝疾病和动脉粥样硬化的新的胆固醇代谢物5-胆甾烯-3β,25-二醇二硫酸酯(25HCDS) |
| EP2842547A1 (en) * | 2013-08-27 | 2015-03-04 | Freund Pharmatec Ltd. | Improved fenofibrate compositions |
| EA201990684A1 (ru) * | 2013-12-24 | 2020-12-30 | Вирджиния Коммонвелт Юниверсити | Способы применения оксигенированных холестеролсульфатов (ocs) |
| WO2016005994A2 (en) * | 2014-07-06 | 2016-01-14 | Gattefosse India Pvt. Ltd. | Pharmaceutical composition comprising solid dispersion of bcs class ii drugs with gelucires |
| BR112017007025A2 (pt) * | 2014-10-10 | 2017-12-12 | Univ Virginia Commonwealth | sulfatos de colesterol oxigenados para terapia de distúrbios causados por pelo menos um de atividade de leptina atenuada e um distúrbio de armazenamento de lipídio |
-
2017
- 2017-08-01 WO PCT/US2017/044934 patent/WO2018026837A1/en not_active Ceased
- 2017-08-01 US US16/320,074 patent/US20200222430A1/en not_active Abandoned
- 2017-08-01 JP JP2019505245A patent/JP7048576B2/ja active Active
- 2017-08-01 AU AU2017305305A patent/AU2017305305A1/en not_active Abandoned
- 2017-08-01 MX MX2019001327A patent/MX391441B/es unknown
- 2017-08-01 CA CA3031215A patent/CA3031215A1/en active Pending
- 2017-08-01 TW TW106125937A patent/TW201818946A/zh unknown
- 2017-08-01 KR KR1020197005440A patent/KR102462275B1/ko active Active
- 2017-08-01 BR BR112019001225-7A patent/BR112019001225A2/pt active Search and Examination
- 2017-08-01 EP EP17837553.1A patent/EP3493810A4/en not_active Withdrawn
- 2017-08-01 CN CN201780059521.6A patent/CN109922811B/zh not_active Expired - Fee Related
-
2019
- 2019-01-22 IL IL264391A patent/IL264391A/en unknown
-
2021
- 2021-11-15 US US17/526,493 patent/US20220175798A1/en not_active Abandoned
-
2022
- 2022-03-24 JP JP2022047697A patent/JP2022084831A/ja not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Pınar et al. | Formulation strategies of nanosuspensions for various administration routes | |
| ud Din et al. | Development, in-vitro and in-vivo evaluation of ezetimibe-loaded solid lipid nanoparticles and their comparison with marketed product | |
| Bhalekar et al. | Formulation and characterization of solid lipid nanoparticles for an anti-retroviral drug darunavir | |
| US9566274B2 (en) | Methods for enhancing the release and absorption of water insoluble active agents | |
| JP2018537513A5 (enExample) | ||
| El-Emam et al. | Formulation and pathohistological study of mizolastine–solid lipid nanoparticles–loaded ocular hydrogels | |
| CA2503719C (en) | Pharmaceutical solutions comprising a modafinil compound and their use for the manufacture of a medicament for treating different diseases | |
| JP2013522230A5 (enExample) | ||
| JP2016516808A5 (enExample) | ||
| JP2020073564A5 (enExample) | ||
| JP2018507891A5 (enExample) | ||
| RU2018126361A (ru) | Композиции, содержащие 15-hepe, и способы их применения | |
| Elkhayat et al. | Ezetimibe-loaded nanostructured lipid carrier for oral delivery: response surface methodology; in vitro characterization and assessing the antihyperlipidemic effect in rats | |
| Sarma et al. | Formulation by Design (FbD) approach to develop Tenofovir Disoproxil Fumarate loaded Nanostructured Lipid Carriers (NLCs) for the aptness of nose to brain delivery | |
| WO2015186039A1 (en) | Oral pharmaceutical composition of isotretinoin | |
| JP2017524021A (ja) | アリピプラゾールプロドラッグ組成物 | |
| JP2014525402A5 (enExample) | ||
| JP2018502163A5 (enExample) | ||
| JP2023522411A (ja) | 経口投与用の新しいカプセル組成物 | |
| EP1330244A1 (en) | Compositions comprising modafinil compounds | |
| JP2017521470A (ja) | イソトレチノインの経口医薬組成物 | |
| JP2008532967A5 (enExample) | ||
| Darweesh et al. | Ezetimibe oral solid lipid nanoparticle by effervescent dispersion method: in vitro characterization and in vivo pharmacokinetic study in rats | |
| JP2015071542A (ja) | 固体分散体の製造方法 | |
| JP7157830B2 (ja) | アリピプラゾールプロドラッグ組成物 |